AR092348A1 - DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc - Google Patents

DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc

Info

Publication number
AR092348A1
AR092348A1 ARP130102439A ARP130102439A AR092348A1 AR 092348 A1 AR092348 A1 AR 092348A1 AR P130102439 A ARP130102439 A AR P130102439A AR P130102439 A ARP130102439 A AR P130102439A AR 092348 A1 AR092348 A1 AR 092348A1
Authority
AR
Argentina
Prior art keywords
alkyl
aminocarbonyl
alkoxy
several times
substituted once
Prior art date
Application number
ARP130102439A
Other languages
English (en)
Inventor
Rene Olivier
Gobbi Alberto
Gaines Simon
Ward Stuart
Bodil Van Niel Monique
Vesey David
Fauber Benjamin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR092348A1 publication Critical patent/AR092348A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/021,2-Thiazines; Hydrogenated 1,2-thiazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02Seven-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D291/00Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/185Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Abstract

Reivindicación 1: Un compuesto de la fórmula (1), o una sal farmacéuticamente aceptable del mismo, en la que: m es el número 0 ó 1; n es el número 0 ó 1; p es un número de 0 a 3; q es el número de 0, 1 ó 2; r es un número de 1 a 3; A es: un enlace; -(CRʲRᵏ)ₜ-; -C(O)-(CRʲRᵏ)ₜ-; -(CRʲRᵏ)ₜ-C(O)-; -NRᵃ-(CRʲRᵏ)ₜ-; -(CRʲRᵏ)ₜ-NRᵃ-; -C(O)NRᵃ-(CRʲRᵏ)ₜ-; -(CRʲRᵏ)ₜ-NRᵃC(O)-; -O-(CRʲRᵏ)ₜ-; -(CRʲRᵏ)ₜ-O-; -S-(CRʲRᵏ)ₜ-; -(CRʲRᵏ)ₜ-S-; -SO₂-(CRʲRᵏ)ₜ-; o -(CRʲRᵏ)ₜ-SO₂-; t es un número de 0 a 4; W es: -CRᵇRᶜ-; -O-; -S-; -SO₂-; o -NRᵈ-; uno de X¹, X², X³ y X⁴ es N y los demás son CRᵉ; o dos de X¹, X², X³ y X⁴ son N y los demás son CRᵉ; o tres de X¹, X², X³ y X⁴ son N y el restante es CRᵉ; o cada uno de X¹, X², X³ y X⁴ es CRᵉ; Y es: -O-; -S-; SO₂-; -CRᶠRᵍ-; o -NRʰ-; Z es: CH; o N; R¹, R², R³, R⁴, R⁵, R⁶, R⁷ y R⁸ con independencia entre sí son: hidrógeno; o alquilo C₁₋₆, que puede estar sin sustituir o sustituido una o varias veces por halógeno; o R³ y R⁴ junto con el átomo al que están unidos pueden formar un grupo etileno; o R³ y R⁴ junto con los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; o R⁵ y R⁶ junto con los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; o R⁷ y R⁸ junto con los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; o uno de R³ y R⁴ junto con uno de R⁵ y R⁶ y los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; o uno de R⁵ y R⁶ junto con uno de R⁷ y R⁸ y los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; cada R⁹ es con independencia: alquilo C₁₋₆; halógeno; alcoxi C₁₋₆; o ciano; dichos restos alquilo C₁₋₆ pueden estar sin sustituir o sustituidos una o varias veces por halógeno; R¹⁰ es: hidrógeno; carboxi; (alquil C₁₋₆)-carbonilo; (alcoxi C₁₋₆)-carbonilo; oxo; hidroxi; aminocarbonilo; N-(alquil C₁₋₆)-aminocarbonilo; N,N-di(alquil C₁₋₆)-aminocarbonilo; ciano; hidroxi-alquilo C₁₋₆; N-(alcoxi C₁₋₆)-(alquil C₁₋₆)-amino-carbonilo; N-hidroxi-(alquil C₁₋₆)-aminocarbonilo; N-(alcoxi C₁₋₆)-aminocarbonilo; halógeno; o alquilo C₁₋₆, que puede estar sin sustituir o sustituido una o varias veces por halógeno u oxo; R¹¹ es: hidrógeno; halógeno; carboxi; (alquil C₁₋₆)-carbonilo; (alcoxi C₁₋₆)-carbonilo; oxo; hidroxi; aminocarbonilo; N-(alquil C₁₋₆)-aminocarbonilo; N,N-di-(alquil C₁₋₆)-aminocarbonilo; (alquil C₁₋₆)-sulfonil-amino; (alquil C₁₋₆)-sulfonil-amino-alquilo C₁₋₆ ciano; hidroxi-alquilo C₁₋₆ N-(alcoxi C₁₋₆)-(alquil C₁₋₆)-aminocarbonilo; N-hidroxi-(alquil C₁₋₆)-aminocarbonilo; N-(alcoxi C₁₋₆)-aminocarbonilo; o alquilo C₁₋₆, que puede estar sin sustituir o sustituido una o varias veces por halógeno u oxo; R¹² es: hidrógeno; halógeno; carboxi; (alquil C₁₋₆)-carbonilo; (alcoxi C₁₋₆)-carbonilo; oxo; hidroxi; aminocarbonilo; N-(alquil C₁₋₆)-aminocarbonilo; N,N-di-(alquil C₁₋₆) -aminocarbonilo; ciano; hidroxi-alquilo C₁₋₆; N-(alcoxi C₁₋₆)-(alquil C₁₋₆)-aminocarbonilo; N-hidroxi-(alquil C₁₋₆)-aminocarbonilo; N-(alcoxi C₁₋₆)-aminocarbonilo; o alquilo C₁₋₆, que puede estar sin sustituir o sustituido una o varias veces por halógeno u oxo; o R¹⁰ y R¹¹ junto con los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; Rᵃ, Rᵇ, Rᶜ y Rᵈ con independencia entre sí son: hidrógeno; o alquilo C₁₋₆, que puede estar sin sustituir o sustituido una o varias veces por halógeno; o Rᵇ y Rᶜ junto con los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; o uno de Rᵇ y Rᶜ junto con uno de R⁷ y R⁸ y los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; o uno de Rᵇ y Rᶜ junto con uno de R⁵ y R⁶ y los átomos a los que están unidos pueden formar un anillo saturado o parcialmente saturado de tres, cuatro, cinco, seis o siete eslabones, que puede incluir opcionalmente uno o dos heteroátomos elegidos entre -O-, -NRᵃ- y -S-, y que puede estar opcionalmente sustituido una o varias veces por Rⁱ; cada Rᵉ es con independencia: hidrógeno; alquilo C₁₋₆; halógeno; alcoxi C₁₋₆; o ciano; dichos restos alquilo C₁₋₆ pueden estar sin sustituir o sustituidos una o varias veces por halógeno; Rᶠ es: hidrógeno; halógeno; o alquilo C₁₋₆, que puede estar sin sustituir o sustituido una o varias veces por halógeno; Rᵍ es: hidrógeno; alquilo C₁₋₆; cicloalquilo C₃₋₆; cicloalquenilo C₃₋₆; (cicloalquil C₃₋₆)-alquilo C₁₋₆; halógeno; (alquil C₁₋₆)-carbonilo; (cicloalquil C₃₋₆)-carbonilo; (cicloalquil C₃₋₆)-(alquil C₁₋₆)-carbonilo; ciano-(alquil C₁₋₆)-carbonilo; hidroxi-(alquil C₁₋₆)-carbonilo; alcoxi C₁₋₆-(alquil C₁₋₆)-carbonilo; carboxi; N-ciano-aminocarbonilo; N-ciano-N-(alquil C₁₋₆)-aminocarbonilo; N-(alquil C₁₋₆)-acetimidamidilo; N,N-di-(alquil C₁₋₆)-acetimidamidilo; N-ciano-N-(alquil C₁₋₆)-acetimidamidilo; N-hidroxi-acetimidamidilo; N-alcoxi C₁₋₆-acetimidamidilo; N-hidroxi-N-(alquil C₁₋₆)-acetimidamidilo; N-(alcoxi C₁₋₆)-N-(alquil C₁₋₆)-acetimidamidilo; 2-nitro-1-N-(alquil C₁₋₆)-amino-vinilo; formilo; (alquil C₁₋₆)-sulfonilo; (cicloalquil C₃₋₆)-sulfonilo; (cicloalquil C₃₋₆)-(alquil C₁₋₆)-sulfonilo; (alquil C₁₋₆)-sulfonil-alquilo C₁₋₆; aminocarbonilo; N-hidroxi-aminocarbonilo; N-(alcoxi C₁₋₆)-aminocarbonilo; N-(alquil C₁₋₆)-aminocarbonilo; aminocarbonil-alquilo C₁₋₆; N-(alquil C₁₋₆)-aminocarbonil-alquilo C₁₋₆; N,N-di-(alquil C₁₋₆)-aminocarbonil-alquilo C₁₋₆; (alcoxi C₁₋₆)-carbonilo; N-hidroxi-N-(alquil C₁₋₆)-aminocarbonilo; N-alcoxi C₁₋₆-N-(alquil C₁₋₆)-aminocarbonilo; N,N-di(alquil C₁₋₆)-aminocarbonilo; aminosulfonilo; N-(alquil C₁₋₆)-aminosulfonilo; N,N-di-(alquil C₁₋₆)-aminosulfonilo; ciano; alcoxi C₁₋₆ (alquil C₁₋₆)-sulfonil-amino; N-(alquil C₁₋₆)-sulfonil-aminocarbonilo; N-(alqui
ARP130102439A 2012-07-11 2013-07-10 DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc AR092348A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261670519P 2012-07-11 2012-07-11
US201361788430P 2013-03-15 2013-03-15
US201361837461P 2013-06-20 2013-06-20

Publications (1)

Publication Number Publication Date
AR092348A1 true AR092348A1 (es) 2015-04-15

Family

ID=48782328

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102439A AR092348A1 (es) 2012-07-11 2013-07-10 DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc

Country Status (21)

Country Link
US (1) US9115101B2 (es)
EP (1) EP2872504B1 (es)
JP (1) JP6262228B2 (es)
KR (1) KR20150029739A (es)
CN (2) CN107235867A (es)
AR (1) AR092348A1 (es)
AU (1) AU2013288756A1 (es)
BR (1) BR112015000581A2 (es)
CA (1) CA2876449A1 (es)
CL (1) CL2014003572A1 (es)
CO (1) CO7141456A2 (es)
CR (1) CR20140548A (es)
ES (1) ES2612165T3 (es)
HK (2) HK1208679A1 (es)
IL (1) IL236293A0 (es)
MX (1) MX2015000325A (es)
PE (1) PE20151007A1 (es)
PH (1) PH12014502788B1 (es)
SG (1) SG11201408534VA (es)
TW (1) TW201408652A (es)
WO (1) WO2014009447A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI519515B (zh) 2011-12-21 2016-02-01 諾維拉治療公司 B型肝炎抗病毒劑
EP3243826B1 (en) 2012-04-26 2019-10-30 Bristol-Myers Squibb Company Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲mPGES-1抑制劑之***酮化合物
EA027280B1 (ru) 2012-08-28 2017-07-31 Янссен Сайенсиз Айрлэнд Юси Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
ME03780B (me) 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
CA2899706C (en) 2013-02-28 2021-10-19 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
US9895349B2 (en) 2013-04-03 2018-02-20 Janssen Sciences Ireland Us N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
BR112015028538A2 (pt) 2013-05-17 2017-07-25 Janssen Sciences Ireland Uc derivados de sulfamoiltiofenamida e o uso dos mesmos como medicamentos para o tratamento da hepatite b
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
KR20160023676A (ko) * 2013-06-21 2016-03-03 에프. 호프만-라 로슈 아게 RORc 조절제로서 아릴 설탐 유도체
NO3024819T3 (es) 2013-07-25 2018-07-21
WO2015027124A1 (en) 2013-08-23 2015-02-26 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
CA2923712C (en) 2013-10-23 2021-11-02 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JP6458041B2 (ja) * 2014-01-10 2019-01-23 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft RORcモジュレーターとしてのアリールスルタム誘導体
ES2760521T3 (es) * 2014-01-10 2020-05-14 Hoffmann La Roche Derivados de aril-sultamo como moduladores de RORc
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
WO2015116904A1 (en) 2014-02-03 2015-08-06 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ror-gamma
RU2702109C1 (ru) 2014-02-05 2019-10-04 Новира Терапьютикс, Инк. Комбинированная терапия для лечения инфекций вгв
CN110483484A (zh) 2014-02-06 2019-11-22 爱尔兰詹森科学公司 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
CN104370755B (zh) * 2014-08-18 2017-04-12 江西隆莱生物制药有限公司 一种光学活性的3‑氨基丁醇和3‑氨基丁酸的制备方法
WO2016061160A1 (en) 2014-10-14 2016-04-21 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ror-gamma
WO2016069496A1 (en) * 2014-10-26 2016-05-06 Galileo Group, Inc. Swarm approach to consolidating and enhancing smartphone target imagery by virtually linking smartphone camera collectors across space and time using machine-to-machine networks
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
EP3233849A1 (en) * 2014-12-17 2017-10-25 F. Hoffmann-La Roche AG HETEROARYLALKYLENE ARYL SULTAM DERIVATIVES AS RORc MODULATORS
BR112017014770A2 (pt) 2015-01-08 2018-01-16 Advinus Therapeutics Ltd compostos bicíclicos, composições e aplicações médicas dos mesmos
WO2016128908A1 (en) 2015-02-12 2016-08-18 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
CN107847762A (zh) 2015-03-19 2018-03-27 诺维拉治疗公司 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2017005668A1 (en) * 2015-07-08 2017-01-12 F. Hoffmann-La Roche Ag ARYL SULTAM DERIVATIVES AS RORc MODULATORS
EP3319962B1 (en) * 2015-07-08 2020-05-13 H. Hoffnabb-La Roche Ag Aryl sultam derivatives as rorc modulators
ES2856931T3 (es) 2015-08-05 2021-09-28 Vitae Pharmaceuticals Llc Moduladores de ROR-gamma
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
EP3356328A1 (en) 2015-09-29 2018-08-08 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
RU2018121946A (ru) 2015-11-20 2019-12-23 Вайтаи Фармасьютиклз, Ллк Модуляторы ror-гамма
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ROR-γ調節劑
EP3442524A2 (en) 2016-04-15 2019-02-20 Novira Therapeutics Inc. Combinations and methods comprising a capsid assembly inhibitor
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
JP7027437B2 (ja) * 2016-10-27 2022-03-01 エスカリア バイオサイエンシーズ,ビーブイ ROR-γモジュレーター
CN106966912B (zh) * 2017-04-01 2019-07-02 沧州那瑞化学科技有限公司 (r)-3-氨基丁醇的制备方法
IL271889B2 (en) 2017-07-10 2023-03-01 Celgene Corp Antisplit compounds and methods of their use
MA49685A (fr) 2017-07-24 2021-04-14 Vitae Pharmaceuticals Llc INHIBITEURS DE ROR gamma
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
WO2019022223A1 (ja) * 2017-07-28 2019-01-31 東レ株式会社 環状アミン誘導体及びその医薬用途
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
EP3765009A4 (en) * 2018-03-12 2021-11-10 Escalier Biosciences, BV BICYCLIC ROR-GAMMA MODULATORS
US11242350B2 (en) 2018-03-12 2022-02-08 Escalier Biosciences B.V. Spirocyclic ROR-gamma modulators
US10973801B2 (en) 2018-03-14 2021-04-13 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
US11096931B2 (en) 2019-02-22 2021-08-24 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
CA3134613A1 (en) 2019-04-02 2020-10-08 Aligos Therapeutics, Inc. Compounds targeting prmt5
US11491148B2 (en) 2019-05-06 2022-11-08 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
IL308122A (en) 2021-06-16 2023-12-01 Celgene Corp Azetidinyl compounds consisting of a carboxylic acid group for the treatment of neurodegenerative diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007051810A2 (en) * 2005-11-01 2007-05-10 Transtech Pharma Pharmaceutical use of substituted amides
CN101351209A (zh) * 2005-11-01 2009-01-21 转化技术制药公司 取代的酰胺的药学应用
WO2011007819A1 (ja) 2009-07-17 2011-01-20 塩野義製薬株式会社 ラクタムまたはベンゼンスルホンアミド化合物を含有する医薬
EP2368886A1 (en) 2010-03-01 2011-09-28 Phenex Pharmaceuticals AG Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease
JP6063870B2 (ja) 2010-11-08 2017-01-18 ライセラ・コーポレイション RORγ活性の阻害用のN−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療
JP6182594B2 (ja) 2012-04-27 2017-08-16 グラクソ グループ リミテッドGlaxo Group Limited 新規化合物

Also Published As

Publication number Publication date
WO2014009447A1 (en) 2014-01-16
PH12014502788A1 (en) 2015-02-09
MX2015000325A (es) 2015-04-14
ES2612165T3 (es) 2017-05-12
CN104470917A (zh) 2015-03-25
CN104470917B (zh) 2017-08-04
EP2872504A1 (en) 2015-05-20
SG11201408534VA (en) 2015-02-27
KR20150029739A (ko) 2015-03-18
CA2876449A1 (en) 2014-01-16
PE20151007A1 (es) 2015-06-29
HK1208679A1 (en) 2016-03-11
US20140031330A1 (en) 2014-01-30
JP6262228B2 (ja) 2018-01-17
TW201408652A (zh) 2014-03-01
CO7141456A2 (es) 2014-12-12
BR112015000581A2 (pt) 2017-06-27
CL2014003572A1 (es) 2015-04-24
PH12014502788B1 (en) 2015-02-09
CR20140548A (es) 2015-02-12
US9115101B2 (en) 2015-08-25
CN107235867A (zh) 2017-10-10
EP2872504B1 (en) 2016-11-16
IL236293A0 (en) 2015-02-26
HK1244781A1 (zh) 2018-08-17
JP2015522057A (ja) 2015-08-03
AU2013288756A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
AR092348A1 (es) DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc
AR094313A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR095464A1 (es) Compuestos de heteroarilo y usos de los mismos
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR106763A1 (es) Oxadiazoles sustituidos para combatir hongos fitopatógenos
AR092108A1 (es) Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR100975A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR100808A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR084553A1 (es) DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER
AR078609A1 (es) 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central,tales como depresion y canceres de ovario y renales, entre otros.
AR112338A2 (es) Arilciclohexiléteres de dihidro-tetraazabenzoazuleno
AR088793A1 (es) Compuestos y metodos para mejorar las respuestas inmunitarias innatas
ES2620668T3 (es) Derivados de amidas y sulfonamidas amido espirocíclicas
AR100418A1 (es) Compuestos y composiciones para inducir condrogénesis
AR094557A1 (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn
AR090590A1 (es) COMPUESTOS 1,3,4-OXADIAZOL Y 1,3,4-TIADIAZOL COMO INHIBIDORES DE b-LACTAMASA
DOP2010000272A (es) Nuevos derivados de carbazol inhibidores de hsp90, composiciones que los contienen y utilizacion
CR20160578A (es) Derivados de indolin-2-ona o pirrolo-piridin-2-ona
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
AR099913A1 (es) Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR095164A1 (es) Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofílica
AR082914A1 (es) Heteroarilmetilamidas utiles para tratar enfermedades cardiovasculares y dislipemias, composiciones farmaceuticas que las contienen y proceso de preparacion de los mismos
AR097866A1 (es) Derivados de 4-azaindol
AR103742A1 (es) Derivados de trifluorometilpropanamida

Legal Events

Date Code Title Description
FB Suspension of granting procedure